7. Other disclosures
7.1 Number of employees
On March 31, 2021, the Sonova Group employed the full time equivalent of 14,508 people (previous year 15,184). They were engaged in the following regions and activities:
By region |
| 31.3.2021 |
| 31.3.2020 |
Switzerland |
| 1,321 |
| 1,290 |
EMEA (excl. Switzerland) |
| 6,443 |
| 6,866 |
Americas |
| 3,415 |
| 3,550 |
Asia/Pacific |
| 3,329 |
| 3,478 |
Total |
| 14,508 |
| 15,184 |
|
|
|
|
|
By activity |
|
|
|
|
Research and development |
| 879 |
| 842 |
Operations |
| 4,398 |
| 4,618 |
Sales and marketing, general and administration |
| 9,231 |
| 9,724 |
Total |
| 14,508 |
| 15,184 |
The average number of employees (full time equivalents) of the Sonova Group for the year was 14,436 (previous year 15,002). Total personnel expenses for the 2020/21 financial year amounted to CHF 940.2 million (previous year CHF 1,037.6 million).
7.2 Transactions and relations with members of the Management Board and the Board of Directors
CHF million |
| 2020/21 |
| 2019/20 |
| 2020/21 |
| 2019/20 |
| 2020/21 |
| 2019/20 |
|
| Management Board |
|
|
| Board of Directors |
|
|
| Total |
|
|
Short-term employee benefits |
| 7.2 |
| 8.6 |
| 1.4 |
| 1.9 |
| 8.5 |
| 10.5 |
Post-employment benefits |
| 0.6 |
| 0.6 |
|
|
|
|
| 0.6 |
| 0.6 |
Share based payments |
| 4.5 |
| 4.8 |
| 1.6 |
| 1.5 |
| 6.2 |
| 6.3 |
Total |
| 12.3 |
| 14.0 |
| 3.0 |
| 3.4 |
| 15.3 |
| 17.4 |
The total compensation to the Management Board for the 2020/21 reporting period, as shown above, relates to nine members of the Management Board (2019/20: nine members).
The total compensation to the Board of Directors for the 2020/21 reporting period, as shown above, relates to nine active members (2019/20: eight members and one former member).
Transactions between the Group and the various post-employment benefit plans for the employees of the Group are described in Note 7.3.
Further information in accordance with Swiss law relating to remuneration and ownership of shares and options of the Board of Directors and the Management Board can be found in the Note 3.6 of the financial statements of Sonova Holding AG.
7.3 Employee benefits
Defined benefit plans
Sonova Groupʼs retirement plans include defined benefit pension plans in Switzerland, Austria, Belgium, Canada, Germany and Israel. These plans are both funded and unfunded and governed by local regulations using independent actuarial valuations according to IAS 19. Sonova Groupʼs major defined benefit plan is located in Switzerland, which in total accounts for CHF 483.9 million or 98.7% (previous year CHF 442.9 million or 99.6%) of Sonovaʼs defined benefit obligation.
Pension plans in Switzerland
The current pension arrangement for employees in Switzerland is made through a plan governed by the Swiss Federal Occupational Old Age, Survivors and Disability Pension Act (BVG). The plan of Sonovaʼs Swiss companies is administered by a separate legal foundation, which is funded by regular employer and employee contributions as defined in the pension fund rules. The Swiss pension plan contains a cash balance benefit which is, in essence, contribution-based with certain minimum guarantees. Due to these minimum guarantees, the Swiss plan is treated as a defined benefit plan for the purposes of these IFRS financial statements, although it has many of the characteristics of a defined contribution plan. The plan is invested in a diversified range of assets in accordance with the investment strategy and the common criteria of an asset and liability management. A potential under-funding may be remedied by various measures such as increasing employer and employee contributions or reducing prospective benefits. Above a set insured salary, the savings capital will be split into pension-accumulating and capital-accumulating savings capital. The pension-accumulating savings capital will generate a life-long retirement pension upon retirement. The capital-accumulating savings capital will generate a one-off capital payment upon retirement. An annuity rate of 5.4% to the individual accumulated retirement savings capital was applied for the financial years 2020/21 and 2019/20.
As of March 31, 2021, 1,363 employees (previous year 1,328 employees) and 143 beneficiaries (previous year 133 beneficiaries) are insured under the Swiss plan. The defined benefit obligation has a duration of 14.0 years (previous year 13.9 years).
The results of all defined benefit plans are summarized below:
Amounts recognized in the balance sheet CHF million |
| 31.3.2021 |
| 31.3.2020 |
Present value of funded obligations |
| (490.1) |
| (444.5) |
Fair value of plan assets |
| 474.1 |
| 375.4 |
Net present value of funded plans |
| (16.0) |
| (69.1) |
Present value of unfunded obligations |
| (5.3) |
| (4.4) |
Total liabilities, net |
| (21.3) |
| (73.5) |
|
|
|
|
|
Amounts in the balance sheet: |
|
|
|
|
Retirement benefit obligation |
| (21.3) |
| (73.5) |
Remeasurements recognized in equity CHF million |
| 2020/21 |
| 2019/20 |
Balance April 1 |
| 77.1 |
| 32.0 |
Actuarial losses/(gains) from |
|
|
|
|
– changes in financial assumptions |
| 10.1 |
| 6.0 |
– changes in experience adjustments |
| 10.8 |
| 15.2 |
Return on plan assets excluding interest income |
| (76.7) |
| 23.9 |
Balance March 31 |
| 21.4 |
| 77.1 |
Amounts recognized in the income statement CHF million |
| 2020/21 |
| 2019/20 |
Current service cost1) |
| 19.3 |
| 15.9 |
Net interest cost |
| 0.3 |
| 0.2 |
Total employee benefit expenses2) |
| 19.6 |
| 16.0 |
1)Excluding Participants’ contributions.
2)The amount recognized in the consolidated income statement 2020/21 has been charged to:
– cost of sales CHF 3.3 million (previous year CHF 2.8 million);
– research and development CHF 6.3 million (previous year 5.3 million);
– sales and marketing CHF 3.9 million (previous year 3.4 million);
– general and administration CHF 5.8 million (previous year CHF 4.3 million);
– financial expenses CHF 0.3 million (previous year CHF 0.2 million).
Movement in the present value of the defined benefit obligations CHF million |
| 2020/21 |
| 2019/20 |
Beginning of the year |
| 448.9 |
| 409.2 |
Interest cost |
| 2.0 |
| 2.3 |
Current service cost |
| 19.3 |
| 15.9 |
Participants’ contributions |
| 12.4 |
| 11.8 |
Benefits paid, net |
| (8.0) |
| (11.4) |
Actuarial loss on obligations |
| 20.9 |
| 21.2 |
Exchange differences |
| (0.1) |
| (0.2) |
Present value of obligations at end of period |
| 495.5 |
| 448.9 |
Movement in the fair value of the plan assets CHF million |
| 2020/21 |
| 2019/20 |
Beginning of the year |
| 375.4 |
| 383.2 |
Interest income on plan asset |
| 1.7 |
| 2.1 |
Employer’s contributions paid |
| 15.3 |
| 13.5 |
Participants’ contributions |
| 12.4 |
| 11.8 |
Benefits paid, net |
| (7.6) |
| (11.3) |
Return on plan assets excluding interest income |
| 76.7 |
| (23.9) |
Exchange differences |
| 0.2 |
| (0.0) |
Fair value of plan assets at end of period |
| 474.1 |
| 375.4 |
The plan assets consist of: |
| 31.3.2021 |
| 31.3.2020 |
Cash |
| 2.6% |
| 2.4% |
Domestic bonds |
| 16.2% |
| 17.0% |
Foreign bonds |
| 7.5% |
| 8.7% |
Domestic equities |
| 12.8% |
| 12.5% |
Foreign equities |
| 31.5% |
| 28.7% |
Real estates |
| 14.8% |
| 16.3% |
Alternative investments |
| 14.6% |
| 14.4% |
All of the plan assets have quoted market prices. The actual return on plan assets amounted to CHF 78.4 million (previous year CHF –21.8 million). The expected employerʼs contributions to be paid in the 2021/22 financial year amount to CHF 14.2 million.
Principal actuarial assumptions (weighted average) |
| 2020/21 |
| 2019/20 |
Discount rate |
| 0.30% |
| 0.45% |
Future salary increases |
| 1.00% |
| 1.00% |
Future pension increases |
| 0% |
| 0% |
Fluctuation rate |
| 10% |
| 10% |
Demography |
| BVG 2015GT |
| BVG 2015GT |
The following sensitivity analysis shows how the present value of the benefit obligation for the Swiss retirement benefit plan would change if one of the principal actuarial assumptions was changed. For the analysis, changes in the assumptions were considered separately and no interdependencies were taken into account.
Sensitivity analysis – impact on defined benefit obligation CHF million |
| 31.3.2021 |
| 31.3.2020 |
Discount rate |
|
|
|
|
Discount rate +0.25% |
| (15.6) |
| (14.2) |
Discount rate –0.25% |
| 17.7 |
| 16.1 |
Salary growth |
|
|
|
|
Salary growth +0.25% |
| 0.8 |
| 0.8 |
Salary growth –0.25% |
| (0.8) |
| (0.8) |
Pension growth |
|
|
|
|
Pension growth +0.5% |
| 18.4 |
| 16.5 |
Pension growth –0.5% |
| (18.4) |
| (16.5) |
Fluctuation rate |
|
|
|
|
Fluctuation rate +5% |
| (19.2) |
| (16.7) |
Fluctuation rate –5% |
| 32.8 |
| 28.6 |
Defined contribution plans
Several of the Groupʼs entities have a defined contribution plan. The employerʼs contributions amounted to CHF 19.6 million in the year ended March 31, 2021 (previous year CHF 23.5 million) and are recognized directly in the income statement.
Accounting policies
Most employees are covered by post-employment plans sponsored by corresponding Group companies in the Sonova Group. Such plans are mainly defined contribution plans (future benefits are determined by reference to the amount of contributions paid) and are generally administered by autonomous pension funds or independent insurance companies. These pension plans are financed through employer and employee contributions. The Groupʼs contributions to defined contribution plans are charged to the income statement in the year to which they relate.
The Group also has several defined benefit pension plans, both funded and unfunded. Accounting and reporting of these plans are based on annual actuarial valuations. Defined benefit obligations and service costs are assessed using the projected unit credit method, with the cost of providing pensions charged to the income statement so as to spread the regular cost over the service lives of employees participating in these plans. The pension obligation is measured as the present value of the estimated future outflows using interest rates of high quality corporate bonds, which have terms to maturity approximating the terms of the related liability. Service costs from defined benefit plans are charged to the appropriate income statement heading within the operating results.
A single net interest component is calculated by applying the discount rate to the net defined benefit asset or liability. The net interest component is recognized in the income statement in the financial result.
Actuarial gains and losses, resulting from changes in actuarial assumptions and differences between assumptions and actual experiences, are recognized in the period in which they occur in “Other comprehensive income” in equity.
Accounting judgements and estimates
The Sonova Group has various employee benefit plans. Most of its salaried employees are covered by these plans, of which some are defined benefit plans. The present value of the defined benefit obligations at the end of the 2020/21 financial year amounts to CHF 495.5 million (previous year CHF 448.9 million). This includes CHF 483.9 million (previous year CHF 442.9 million) from the Swiss pension plan. With such plans, actuarial assumptions are made for the purpose of estimating future developments, including estimates and assumptions relating to discount rates, and future wage as well as pension trends. Actuaries also use statistical data such as mortality tables and staff turnover rates with a view to determining employee benefit obligations. If these factors change due to a change in economic or market conditions, the subsequent results could deviate considerably from the actuarial reports and calculations. In the medium term, such deviations could have an impact on the equity.
7.4 Equity plans
Equity plans are offered annually to the members of the Board of Directors (BoD), to the members of the Management Board (MB) as well as to other management and senior employees of the Group, entitling them to receive long-term incentives in the form of equity plans free of charge. Equity plans are settled either with Sonova Holding AG shares (equity-settled share-based payment) or for certain US employees with an equivalent amount in cash (cash-settled share-based payment). The amount granted varies depending on the degree of management responsibility held.
In the 2020/21 and 2019/20 financial years, as part of the Executive Equity Award Plan (EEAP) Sonova granted restricted shares, restricted share units (RSUs), performance share units (PSUs), options, and for US employees, share appreciation rights (SARs). Options as well as PSUs granted to the Management Board in 2020/21 and 2019/20 include a performance criterion.
The following share-based payment costs have been recognized in the financial years:
CHF million |
| 2020/21 |
| 2019/20 |
Equity-settled share-based payment costs |
| 20.4 |
| 19.3 |
Cash-settled share-based payment costs |
| 10.9 |
| 0.6 |
Total share-based payment costs |
| 31.3 |
| 19.9 |
The increase in cash-settled share-based payment costs in the current financial year was primarily driven by the change in accounting treatment for an acquisition in 2019/20. For further information please refer to Note 6.1 and to section “restricted shares” in this note.
The following table shows the outstanding options and/or SARs, granted as part of the EEAP 2015 to 2021. All of the equity instruments listed below (except for the non-recurring performance options granted to the COO (now CEO) in 2017/18) vest in 4 equal tranches, annually over a period of 4 years. The non-recurring performance options granted to the CEO vest earliest on April 1, 2023, subject to the achievement of the performance criteria.
Summary of outstanding options and SARs granted until March 31, 2021: | ||||||||||||||
Financial year granted |
| Instruments granted |
| First vesting date/ expiry date |
| Granted |
| Exercise price (CHF) |
| Outstanding |
| Average remaining life (years) |
| Exercisable |
2014/15 |
| Options/SARs1) |
| 1.6.2016 31.1.2022 |
| 308,459 |
| 121.10 |
| 21,689 |
| 0.8 |
| 21,689 |
2015/16 |
| Options/SARs2) |
| 1.6.2017 31.1.2023 |
| 298,520 |
| 124.20 |
| 77,550 |
| 1.8 |
| 77,550 |
2016/17 |
| Options/SARs3) |
| 1.6.2018 31.1.2024 |
| 378,652 |
| 130.00 |
| 167,426 |
| 2.8 |
| 102,584 |
2017/18 |
| Options4) |
| 1.4.2023 30.9.2027 |
| 47,415 |
| 147.85 |
| 47,415 |
| 6.5 |
|
|
2017/18 |
| Options/SARs5) |
| 1.6.2019 31.1.2028 |
| 341,943 |
| 147.85 |
| 226,349 |
| 6.8 |
| 91,881 |
2018/19 |
| Options/SARs6) |
| 1.6.2020 31.1.2029 |
| 249,760 |
| 182.40 |
| 212,867 |
| 7.8 |
| 47,404 |
2019/20 |
| Options/SARs7) |
| 1.6.2021 31.1.2030 |
| 208,245 |
| 241.80 |
| 195,478 |
| 8.8 |
|
|
2020/21 |
| Options/SARs8) |
| 1.6.2022 31.1.2031 |
| 170,694 |
| 218.70 |
| 170,694 |
| 9.8 |
|
|
Total |
|
|
|
|
| 2,003,688 |
|
|
| 1'119'4689) |
| 6.8 |
| 341'10810) |
Thereof: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-settled |
|
|
|
|
| 1,774,782 |
|
|
| 1,005,440 |
|
|
| 310,167 |
Cash-settled |
|
|
|
|
| 228,906 |
|
|
| 114,028 |
|
|
| 30,941 |
1)Including 135,223 performance options, granted to the CEO and MB members.
2)Including 126,206 performance options, granted to the CEO and MB members.
3)Including 147,948 performance options, granted to the CEO and MB members.
4)Non-recurring performance options, granted to the COO (now CEO). Terms have been amended in the financial year 2020/21 – for further details refer to section "Options" in this note.
5)Including 150,114 performance options, granted to the CEO and MB members.
6)Including 80,850 performance options, granted to the CEO and MB members.
7)Including 77,574 performance options/SAR, granted to the CEO and MB members.
8)Including 61,779 performance options/SAR, granted to the CEO and MB members.
9)Weighted average exercise price of outstanding options/SARs amounts to CHF 176.80
10)Weighted average exercise price for exercisable options/SARs amounts to CHF 140.21
The fair value of options and/or SARs is calculated at the grant date by using an “Enhanced American Pricing Model”. The expected volatility is based on historical measures. The main valuation assumptions used for the options and/or SARs granted in the current and in the previous financial year are as follows:
Assumptions for valuation at grant date |
| EEAP 2021 – Management Board Options/SARs |
| EEAP 2021 Options/SARs |
| EEAP 2020 – Management Board Options/SARs |
| EEAP 2020 Options/SARs |
Valuation date |
| 1.2.2021 |
| 1.2.2021 |
| 1.2.2020 |
| 1.2.2020 |
Expiry date |
| 31.01.2031 |
| 31.01.2031 |
| 31.01.2030 |
| 31.01.2030 |
Restriction period |
| 5 years |
|
|
| 5 years |
|
|
Share price on grant date |
| CHF 218.70 |
| CHF 218.70 |
| CHF 241.80 |
| CHF 241.80 |
Exercise price |
| CHF 218.70 |
| CHF 218.70 |
| CHF 241.80 |
| CHF 241.80 |
Volatility |
| 25.0% |
| 25.0% |
| 20.3% |
| 20.3% |
Expected dividend yield |
| 1.5% |
| 1.5% |
| 1.6% |
| 1.6% |
Weighted risk free interest rate |
| (0.4%) |
| (0.5%) |
| (0.5%) |
| (0.6%) |
Weighted average fair value of options/SARs issued |
| 39.90 |
| 37.31 |
| 33.34 |
| 31.98 |
Options
The exercise price of options is equal to the market price of Sonova Holding AG shares on the SIX Swiss Exchange at grant date. The fair value of the options granted is estimated at grant date and recorded as an expense over the corresponding vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period (including adjustments due to re-assessments of the likely ROCE targets achievements for performance options granted to the CEO and the other members of the MB) to ensure that only a charge for vested amounts occur. Options may be exercised after the vesting date, until their expiry date. If options are exercised, one share per option from the conditional share capital is issued, or treasury shares are used for fulfillment. In the financial year 2020/21 and 2019/20 the options granted to the CEO and the members of the MB include a restriction period of 5 years, which was considered in the fair value of the options at grant date.
Given the COVID-19 crisis in the current financial year and the impacts on the business, the Board of Directors reviewed the terms of the one-time, non-recurring performance option award granted to the CEO in the financial year 2017/18 and decided on the following amendments: While the EPS performance target remains as originally set, the performance period will be extended to April 1, 2025. The CEO may elect to have the options vest at the original date of April 1, 2023 or in the interim year on April 1, 2024. The expiry date of the options (September 27, 2027) remains unchanged. The amendment of the performance period did not lead in an increase of the fair value of the options granted (initially CHF 1.0 million).
Changes in outstanding options: |
| 2020/21 |
| 2019/20 | ||||
|
| Number of options |
| Weighted average exercise price (CHF) |
| Number of options |
| Weighted average exercise price (CHF) |
Outstanding options at April 1 |
| 1,010,087 |
| 165.54 |
| 1,147,865 |
| 142.76 |
Granted1) |
| 149,592 |
| 218.70 |
| 182,407 |
| 241.80 |
Exercised2) |
| (126,260) |
| 133.16 |
| (248,711) |
| 125.49 |
Forfeited |
| (27,979) |
| 194.12 |
| (71,474) |
| 145.40 |
Outstanding options at March 31 |
| 1,005,440 |
| 175.89 |
| 1,010,087 |
| 165.54 |
Exercisable at March 31 |
| 310,167 |
| 139.99 |
| 216,608 |
| 129.56 |
1)2020/21 includes 57,080 performance options (previous year 72,176 performance options), granted to the CEO and MB members.
2)The total consideration from options exercised amounted to CHF 29.9 million (previous year CHF 27.9 million). The weighted average share price of the options exercised during the year 2020/21 was CHF 204.63 (previous year CHF 223.68).
Share appreciation rights (SARs)
The exercise price of SARs is generally equal to the market price of Sonova Holding AG shares on the SIX Swiss Exchange at grant date. Upon exercise of SARs, an employee shall be paid, an amount in cash equal to the number of shares for which the employee exercised SARs, multiplied by any surplus, of the per share market price at the date of exercise versus the per share exercise price (determined at the date of grant of SARs). The initial fair value of the SARs is in line with the valuation of the options of the respective period and recorded as an expense over the corresponding vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period (including adjustments due to re-assessments of the likely ROCE targets achievements for performance options/SARs granted to the members of the MB) to ensure that only a charge for vested amounts occur. Until the liability is settled, it is revalued at each reporting date recognizing changes in fair value in the income statement. The SARs may be sold after the vesting date, until they expire, except for the SARs granted to members of the MB in the financial year 2020/21, which include a restriction period of 5 years.
Changes in outstanding SARs: |
| 2020/21 |
| 2019/20 |
| ||||
|
| Number of SARs |
| Weighted average exercise price (CHF) |
| Number of SARs |
| Weighted average exercise price (CHF) |
|
Outstanding SARs at April 1 |
| 107,966 |
| 173.87 |
| 113,024 |
| 148.27 |
|
Granted1) |
| 21,102 |
| 218.70 |
| 25,838 |
| 241.80 |
|
Exercised |
| (10,903) |
| 136.57 |
| (22,168) |
| 128.22 |
|
Forfeited |
| (4,137) |
| 198.35 |
| (8,728) |
| 159.37 |
|
Outstanding SARs at March 312) |
| 114,028 |
| 184.84 |
| 107,966 |
| 173.87 |
|
Exercisable at March 313) |
| 30,941 |
| 142.38 |
| 19,861 |
| 128.61 |
|
1)2020/21 includes 4,699 performance SARs granted to an MB member.
2)The carrying amount of the liability relating to the SARs at March 31, 2021 is CHF 6.8 million (previous year CHF 3.6 million).
3)The intrinsic value of the SARs exercisable at March 31, 2021 amounts to CHF 3.3 million (previous year CHF 0.9 million).
Performance share units (PSUs)
In 2021, as well as in the previous year, grants made to the members of the Management Board under the EEAP consist of PSUs. The PSUs are measured on relative TSR (rTSR) against the constituents of a recognized index. The fair value of a PSU at grant date was based on a “Monte-Carlo valuation”. PSUs entitle the holder up to two shares per PSU, subject to the achievement of the performance criterion. PSUs granted in 2021 are subject to a restriction period, which was considered in the fair value of the PSU at grant date. Upon vesting of the PSUs, the respective shares are either created out of the conditional share capital or treasury shares are used. The cost of the PSUs granted is expensed over their vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period, to ensure that only vested amounts are expensed.
Assumptions for valuation at grant date |
| PSU 2021 |
| PSU 2020 |
Valuation date |
| 1.2.2021 |
| 1.2.2020 |
Date of grant |
| 1.2.2021 |
| 1.2.2020 |
Share price on grant date |
| CHF 218.70 |
| CHF 241.80 |
Fair value |
| CHF 198.67 |
| CHF 266.80 |
End of restriction period |
| 31.1.2026 |
| 31.1.2025 |
Performance conditions |
| Total shareholder return (TSR) |
| Total shareholder return (TSR) |
TSR performance period |
| 1.2.2021 – 31.3.2024 |
| 1.2.2020 – 31.3.2023 |
TSR comparator group |
| Swiss Leader Index (SLI) |
| Swiss Leader Index (SLI) |
Restricted share units (RSUs)
Under the EEAP grants 2015 to 2021, entitled employees have been granted RSUs. The value of an RSU is equal to the market price of Sonova Holding AG shares on the SIX Swiss Exchange on the grant date, adjusted for the fair value of expected dividends, as RSUs are not entitled to dividends. RSUs entitle the holder to one share per RSU after the vesting period. In the case of RSUs granted to the CEO (2014 to 2018) and the other members of the MB (EEAP 2014 to 2017), vesting of these shares is dependent on the fulfillment of the performance criteria which remains the achievement of a pre-defined minimum return on capital employed (ROCE) target. Upon vesting of the RSUs, the respective shares are either created out of the conditional share capital or treasury shares are used. The cost of the RSUs granted is expensed over their vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period to ensure that only vested amounts are expensed.
Restricted shares
In addition to the PSUs granted in respect to the EEAP 2021 and 2020, restricted shares have been granted to the Chairman of the Board of Directors as well as to the other members of the Board of Directors in the financial year 2020/21 and 2019/20. These shares are entitled to dividends and are restricted for a period of 64 months (Chairman), respectively 52 months (other members of the Board of Directors).
The costs for the restricted shares granted to the members of the Board of Directors have been fully expensed in the 2020/21 financial year as these shares have no vesting period.
Changes in outstanding PSUs/RSUs/Restricted shares: |
| 2020/21 |
| 2019/20 | ||||||||||||
|
| Number of PSUs |
| Number of RSUs |
| Number of restricted shares |
| Total |
| Number of PSUs |
| Number of RSUs |
| Number of restricted shares |
| Total |
Balance April 1 |
| 31,689 |
| 259,065 |
| 60,258 |
| 351,012 |
| 25,877 |
| 305,436 |
| 68,574 |
| 399,887 |
Granted |
| 10,359 |
| 68,605 |
| 7,539 |
| 86,503 |
| 8,284 |
| 63,075 |
| 6,157 |
| 77,516 |
Settled |
|
|
| (78,670) |
| (14,206) |
| (92,876) |
|
|
| (87,669) |
| (14,473) |
| (102,142) |
Forfeited |
| (1,804) |
| (15,843) |
|
|
| (17,647) |
| (2,472) |
| (21,777) |
|
|
| (24,249) |
Balance March 31 |
| 40,244 |
| 233,157 |
| 53,591 |
| 326,992 |
| 31,689 |
| 259,065 |
| 60,258 |
| 351,012 |
In the current financial year 2020/21, a change in accounting treatment relating to an acquisition in 2019/20, led to a correction of previously recognized purchase considerations (refer Note 6.1). A portion of the deferred payments can be settled in Sonova shares (number of shares granted 102,421) or in cash at the discretion of the counterparties and represent share-based payments as the payment is linked to employment conditions. The fair value of the shares granted of CHF 21.3 million was calculated at grant date (July 8, 2019) representing the share price on that date and considering that the shares are not entitled to dividends. The associated cost is expensed over the vesting period (four equal tranches vesting equally over four years). Until the liability is settled, it is revalued at each reporting date recognizing changes in the fair value in the income statement. Due to the discretion of the counterparties to request cash payments, the equity plan is classified as a “cash-settled share based payment plan”. For this cash-settled share based payment plan, the corresponding liability is recorded under "Other short-term operating liabilities" in the balance sheet (CHF 11.8 million as per March 31, 2021). The first tranche vested in the financial year 2020/21 and a liability of CHF 5.1 million has been transferred to equity as the beneficiaries opted for settlement in Sonova shares.
Accounting policies
The Board of Directors of Sonova Holding AG, the Management Board, and certain management and senior employees of other Group companies participate in equity compensation plans. The fair value of all equity compensation awards granted to employees is determined at the grant date and recorded as an expense over the vesting period. The expense for equity compensation awards is charged to the appropriate income statement heading within the operating result and an equivalent increase in equity (for equity-settled compensation) or financial liability (for cash-settled compensation) is recorded. In the case of cash-settled compensation, until the liability is settled, it is revalued at each reporting date, recognizing changes in the fair value in the income statement.
7.5 Government grants
The Groupʼs result for the financial year 2020/21 includes government support received worldwide in connection with the COVID-19 pandemic in the amount of CHF 47.4 million (prior year: none). Most of the government grants relate to compensation of salary costs (furlough) and is recognized as a deduction from the costs in the following functional line items of the consolidated income statement:
April 1 to March 31, CHF million |
| 2020/21 |
|
Cost of sales |
| 4.9 |
|
Research and development |
| 2.1 |
|
Sales and marketing |
| 33.7 |
|
General and administration |
| 6.7 |
|
Total |
| 47.4 |
|
Accounting policies
Government grants are recognized when there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. Government grants are presented as a deduction from the relevant functional cost line item in the income statement.
7.6 Events after the balance sheet date
On May 7, 2021 the Group announced that it signed an agreement to acquire the Consumer Division from Sennheiser electronic GmbH & Co. KG (Sennheiser). The product offering of the Consumer Division includes premium headphones – especially in the True Wireless segment – as well as audiophile headphones, enhanced hearing solutions and soundbars. They are sold through a well-established distribution network by Sennheiserʼs own subsidiaries and long-established trading partners in more than 50 countries, both online and in-store, further expanding Sonovaʼs channel presence and customer base. The Sennheiser Consumer Division, with currently around 600 employees contributing to this business area worldwide, generates sales of around EUR 250 million annually. The purchase price for the Sennheiser Consumer Division amounts to EUR 200 million, which will be financed through the existing cash balance. A licensing agreement on customary terms for the Sennheiser brand will be in place in perpetuity. Closing is foreseen in the second half of calendar year 2021 after obtaining the relevant regulatory approvals.
Besides the above mentioned transaction there have been no material events after the balance sheet date.
7.7 List of significant companies
Company name |
| Activity |
| Domicile (country) |
| Share/paid-in capital1) Local currency 1,000 |
| Shares held | ||
|
|
|
|
|
|
|
|
|
|
|
Switzerland |
|
|
|
|
|
|
|
|
|
|
Sonova Holding AG |
| A |
| Stäfa |
| CHF |
| 3,220 |
|
|
Sonova AG |
| A, B, C, D |
| Stäfa |
| CHF |
| 2,500 |
| 100% |
Advanced Bionics AG |
| A, B |
| Stäfa |
| CHF |
| 4,350 |
| 100% |
|
|
|
|
|
|
|
|
|
|
|
EMEA (excluding Switzerland) |
|
|
|
|
|
|
|
|
|
|
Sonova Audiological Care Austria GmbH |
| B |
| Wals-Himmelreich (AT) |
| EUR |
| 450 |
| 100% |
Sonova Retail Belgium NV |
| B |
| Groot-Bijgaarden (BE) |
| EUR |
| 3,686 |
| 100% |
Sonova Deutschland GmbH |
| B |
| Fellbach-Oeffingen (DE) |
| EUR |
| 41 |
| 100% |
Sonova Retail Deutschland GmbH |
| B |
| Dortmund (DE) |
| EUR |
| 1,000 |
| 100% |
Sonova Retail Denmark ApS |
| B |
| Klampenborg (DK) |
| DKK |
| 1,621 |
| 100% |
Sonova Ibérica S.A.U. |
| B |
| Alicante (ES) |
| EUR |
| 7,000 |
| 100% |
Sonova Audiological Care France SAS |
| B |
| Cahors (FR) |
| EUR |
| 58,800 |
| 100% |
SOD Invest SAS |
| B |
| Cahors (FR) |
| EUR |
| 58,600 |
| 100% |
Sonova France S.A.S. |
| B |
| Bron-Lyon (FR) |
| EUR |
| 1,000 |
| 100% |
Sonova Italia Srl |
| B |
| Milan (IT) |
| EUR |
| 1,040 |
| 100% |
AudioNova Italia |
| B |
| Milan (IT) |
| EUR |
| 1,166 |
| 100% |
Sonova Audiological Care Nederland B.V. |
| B |
| Dortrecht (NL) |
| EUR |
| 19 |
| 100% |
Sonova Audiological Care Polska Sp.z.o.o. |
| B |
| Lodz (PL) |
| PLN |
| 678 |
| 100% |
Boots Hearing Care Ltd. |
| B |
| Conwy (UK) |
| GBP |
| 0 | 2) | 51% |
Sonova UK Ltd. |
| B |
| Warrington (UK) |
| GBP |
| 2,500 |
| 100% |
Sonova Service Center UK Limited |
| C |
| Warrington (UK) |
| GBP |
| 3,150 |
| 100% |
Sonova Nordic AB |
| B |
| Solna (SE) |
| SEK |
| 200 |
| 100% |
Sonova Finland Oy |
| B |
| Tampere (FI) |
| EUR |
| 25 |
| 100% |
Sonova Norway AS |
| B |
| Oslo (NO) |
| NOK |
| 1,854 |
| 100% |
Sonova Israel Ltd. |
| B |
| Haifa (IL) |
| ILS |
| 5,150 |
| 100% |
Activities:
AHolding/Finance: The entity is a holding or finance company.
BSales: The entity performs sales and marketing activities.
CProduction: This entity performs manufacturing for the Group.
DResearch: This entity performs research and development activities for the Group.
1)Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.
2)GBP 133
Company name |
| Activity |
| Domicile (country) |
| Share/paid-in capital1) Local currency 1,000 |
| Shares held | ||
|
|
|
|
|
|
|
|
|
|
|
Americas |
|
|
|
|
|
|
|
|
|
|
Sonova do Brasil Produtos Audiológicos Ltda. |
| B |
| Sao Paulo (BR) |
| BRL |
| 120,379 |
| 100% |
National Hearing Services Inc. |
| B |
| Victoria BC (CA) |
| CAD |
| 0 | 2) | 100% |
Sonova Canada Inc. |
| B |
| Mississauga (CA) |
| CAD |
| 0 | 2) | 100% |
Connect Hearing Inc. |
| B |
| Naperville (US) |
| USD |
| 0 | 3) | 100% |
Sonova USA, Inc. |
| B |
| Plymouth (US) |
| USD |
| 46,608 |
| 100% |
Advanced Bionics Corp. |
| A |
| Valencia (US) |
| USD |
| 1 |
| 100% |
Advanced Bionics LLC |
| B, C, D |
| Valencia (US) |
| USD |
| 0 | 2) | 100% |
Sonova United States Hearing Instruments, LLC |
| A |
| Aurora (US) |
| USD |
| 0 | 2) | 100% |
Development Finance Inc. |
| A |
| Wilmington (US) |
| USD |
| 0 | 4) | 100% |
|
|
|
|
|
|
|
|
|
|
|
Asia/Pacific |
|
|
|
|
|
|
|
|
|
|
Sonova Audiological Care Australia Pty. Ltd |
| B |
| McMahons Point (AU) |
| AUD |
| 58,000 |
| 100% |
Sonova Australia Pty Ltd |
| B |
| Baulkham Hills (AU) |
| AUD |
| 10,475 |
| 100% |
Sonova (Shanghai) Co., Ltd. |
| B |
| Shanghai (CN) |
| CNY |
| 20,041 |
| 100% |
Sonova Hearing (Suzhou) Co., Ltd. |
| C |
| Suzhou (CN) |
| CNY |
| 46,249 |
| 100% |
Sonova Japan Co., Ltd. |
| B |
| Tokyo (JP) |
| JPY |
| 10,000 |
| 100% |
Triton Hearing Ltd. |
| B |
| Auckland (NZ) |
| NZD |
| 20,450 |
| 100% |
Sonova Operation Center Vietnam Co., Ltd. |
| C |
| Binh Duong (VN) |
| VND |
| 36,156,000 |
| 100% |
Activities:
AHolding/Finance: The entity is a holding or finance company.
BSales: The entity performs sales and marketing activities.
CProduction: This entity performs manufacturing for the Group.
DResearch: This entity performs research and development activities for the Group.
1)Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.
2)Without par value
3)USD 1
4)USD 10
7.8 Other accounting policies
Investments in subsidiaries
Investments in subsidiaries are fully consolidated. These are entities over which Sonova Holding AG directly or indirectly exercises control. Control exists when the Group is exposed, or has rights, to variable returns from its relationship with an entity and has the power to affect those returns. Control is presumed to exist when the parent owns, directly or indirectly through subsidiaries, more than half of the voting power of an entity unless, in exceptional circumstances, it can clearly demonstrate that such ownership does not constitute control. For the consolidated entities, 100% of assets, liabilities, income, and expenses are included. Non-controlling interests in equity and net income or loss are shown separately in the balance sheet and income statement. Changes in the ownership interest of a subsidiary that do not result in a loss of control will be accounted for as an equity transaction. Hence, neither goodwill nor any gains or losses will result.
Group Companies acquired during the year are included in the consolidation from the date on which control over the company transferred to the Group. Group companies divested during the year are excluded from the consolidation as of the date the Group ceased to have control over the company. Intercompany balances and transactions (including unrealized profit on intercompany inventories) are eliminated in full.
Related parties
A party is related to an entity if the party directly or indirectly controls, is controlled by, or is under common control with the entity, has an interest in the entity that gives it significant influence over the entity, has joint control over the entity or is an associate or a joint venture of the entity. In addition, members of the Board of Directors and the Management Board or close members of their families are also considered related parties as well as post-employment plan organizations (pension funds) for the benefit of Sonova employees. No related party exercises control over the Group.